Evidence map›Paper›PMID 26699276›Full record

ArticleASN neuro

Ganglioside-Dependent Neural Stem Cell Proliferation in Alzheimer's Disease Model Mice.

Noah A Koon, Yutaka Itokazu, Robert K Yu

Open access · goldAbstract read
In one paragraph

Article in ASN neuro. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Therapeutic Candidates for Alzheimer's Disease: Saponins.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Gangliosides in Nerve Cell Specification.Progress in molecular biology and translational science · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Noah A KoonDepartment of Neuroscience and Regenerative Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA Charlie Norwood VA Medical Center, Augusta, GA 30904, USA ryu@gru.edu.
Yutaka ItokazuDepartment of Neuroscience and Regenerative Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA Charlie Norwood VA Medical Center, Augusta, GA 30904, USA.
Robert K YuDepartment of Neuroscience and Regenerative Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA Charlie Norwood VA Medical Center, Augusta, GA 30904, USA.
Charlie Norwood VA Medical Center · USAugusta University · US

Funding

Spingoglycolipids of normal and pathological brainsR01NS011853 · NINDS · YALE UNIVERSITY · PI YU, ROBERT K. · 1985 to 2010
$3.5M
ROLE OF GLYCOLIPIDS IN EXPERIMENTAL NEUROPATHYR01NS026994 · NINDS · VIRGINIA COMMONWEALTH UNIVERSITY · PI YU, ROBERT K. · 1988 to 2012
$3.3M
NINDS NIH HHS R01 NS11853NINDS NIH HHS R01 NS26994
6 · The paper itself

Abstract

The aggregation and formation of amyloid plaques by amyloid β-peptides (Aβs) is believed to be one of the pathological hallmarks of Alzheimer's disease (AD). Intriguingly, Aβs have also been shown to possess proliferative effects on neural stem cells (NSCs). Many essential cellular processes in NSCs, such as fate determination and proliferation, are heavily influenced by cell surface glycoconjugates, including gangliosides. It has recently been shown that Aβ1-42 alters several key glycosyltransferases and glycosidases. To further define the effects of Aβs and to clarify the potential mechanisms of action of those peptides on NSCs, NSCs were cultured from embryonic brains of the double-transgenic mouse model of AD [B6C3-Tg(APPswe,PSEN1dE9)85Dbo/J] coexpressing mutants of amyloid precursor protein (APPswe) and presenilin1 (PSEN1dE9). We found that Aβs not only promoted cell proliferation but also altered expression of several key glycogenes for glycoconjugate metabolism, such as sialyltransferases II and III (ST-II & -III) in AD NSCs. In addition, we found upregulation of epidermal growth factor receptor and Notch1 intracellular domain. Moreover, the increased expression of ST-II and -III coincided with the elevated levels of c-series gangliosides (A2B5+ antigens) in AD NSCs. Further, we revealed that epidermal growth factor signaling and gangliosides are necessary components on Aβ-stimulated NSC proliferation. Our present study has thus provided a novel mechanism for the upregulation of c-series ganglioside expression and increases in several NSC markers to account for the proliferative effect of Aβs on NSCs in AD mouse brain. These observations support the potential beneficial effects of Aβs and gangliosides in promoting neurogenesis in AD brain.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsBrainCells, CulturedDisease Models, AnimalEpidermal Growth FactorGangliosidesGlycosyltransferasesHumansMice, TransgenicMutationNeural Stem CellsNeurogenesisPresenilin-1Amyloid beta-PeptidesAmyloid beta-Protein PrecursorAPP protein, humanEpidermal Growth FactorGangliosidesGlycosyltransferasesPresenilin-1PSEN1 protein, humanAlzheimer’s diseaseamyloid β-peptidecell proliferationglycogeneglycosyltransferaseneural stem cell

Identifiers

PMID26699276
PMCPMC4710121
OpenAlexW2219778249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.